- Home
- KIND vs DAWN Comparison
KIND vs DAWN Comparison
Compare KIND & DAWN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KIND
- DAWN
- Stock Information
- Founded
- KIND 2011
- DAWN 2018
- Country
- KIND United States
- DAWN United States
- Employees
- KIND N/A
- DAWN N/A
- Industry
- KIND Computer Software: Programming Data Processing
- DAWN Biotechnology: Pharmaceutical Preparations
- Sector
- KIND Technology
- DAWN Health Care
- Exchange
- KIND Nasdaq
- DAWN Nasdaq
- Market Cap
- KIND 974.5M
- DAWN 1.3B
- IPO Year
- KIND N/A
- DAWN 2021
- Fundamental
- Price
- KIND $2.42
- DAWN $12.79
- Analyst Decision
- KIND Hold
- DAWN Strong Buy
- Analyst Count
- KIND 2
- DAWN 7
- Target Price
- KIND $2.75
- DAWN $36.17
- AVG Volume (30 Days)
- KIND 2.3M
- DAWN 937.9K
- Earning Date
- KIND 11-06-2024
- DAWN 10-30-2024
- Dividend Yield
- KIND N/A
- DAWN N/A
- EPS Growth
- KIND N/A
- DAWN N/A
- EPS
- KIND N/A
- DAWN N/A
- Revenue
- KIND $237,605,000.00
- DAWN $101,953,000.00
- Revenue This Year
- KIND $14.90
- DAWN N/A
- Revenue Next Year
- KIND $14.61
- DAWN $36.10
- P/E Ratio
- KIND N/A
- DAWN N/A
- Revenue Growth
- KIND 9.99
- DAWN N/A
- 52 Week Low
- KIND $1.32
- DAWN $11.94
- 52 Week High
- KIND $3.00
- DAWN $18.07
- Technical
- Relative Strength Index (RSI)
- KIND 41.53
- DAWN 39.97
- Support Level
- KIND $2.26
- DAWN $12.26
- Resistance Level
- KIND $2.68
- DAWN $12.81
- Average True Range (ATR)
- KIND 0.13
- DAWN 0.52
- MACD
- KIND -0.03
- DAWN -0.05
- Stochastic Oscillator
- KIND 16.04
- DAWN 28.94
About KIND Nextdoor Holdings Inc.
Nextdoor Holdings Inc is the platform to connect to the neighborhoods. The purpose is to cultivate a kinder world where everyone has a neighborhood. Neighbors around the world turn to Nextdoor daily to receive trusted information, give and get help, get things done, and build real-world connections with nearby neighbors, businesses, and public services.
About DAWN Day One Biopharmaceuticals Inc.
Day One Biopharmaceuticals Inc is a clinical-stage biopharmaceutical company. It is dedicated towards developing and commercializing targeted therapies for patients of all ages with genetically defined cancers. Initially, it focuses on clinical development efforts on pediatric patients living with cancer, a vulnerable population that has been underserved in the recent revolution in targeted therapeutics and immuno-oncology. The product candidate, DAY101, is an oral, brain-penetrant, highly-selective type II pan-rapidly accelerated fibrosarcoma, or pan-RAF, kinase inhibitor.